Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | SDCBP | O00560 | 1/20 | 0.41 |
| ▸ | SDC2 | P34741 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ELOC | Q15369 | 3/20 | 0.39 |
| ▸ | ELOB | Q15370 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21107299 | 0.84 | VHL (0.69) | VHLL3MBTL1MAPTNAMPTTDP1 | |
| SCHEMBL25348347 | 0.82 | VHL (0.55) | VHLMEN1KMT2AGAAELOC | |
| SCHEMBL21616147 | 0.82 | VHL (0.50) | VHLL3MBTL1MAPTNPSR1RECQL | |
| SCHEMBL25219455 | 0.82 | L3MBTL1 (0.50) | VHLL3MBTL1MAPTNPSR1RECQL | |
| SCHEMBL30519936 | 0.82 | VHL (0.50) | VHLL3MBTL1MAPTNPSR1RECQL | |
| SCHEMBL30520169 | 0.80 | ABCB1 (0.41) | VHLMAPTMEN1KMT2AELOC | |
| SCHEMBL21612885 | 0.78 | VHL (0.49) | VHLL3MBTL1MAPTNPSR1RECQL | |
| SCHEMBL30520121 | 0.77 | VHL (0.45) | VHLL3MBTL1MAPTNPSR1RECQL | |
| SCHEMBL24455110 | 0.75 | L3MBTL1 (0.51) | L3MBTL1MAPTNPSR1RECQLNAMPT | |
| SCHEMBL3180689 | 0.74 | L3MBTL1 (0.61) | L3MBTL1MAPTNPSR1RECQLNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145609-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-08 | — | — | US | disclosed |
| EP-4476225-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | Aurigene Oncology Limited (IN) | 2024-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145609-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | SMARCC1, SMARCC2, SMARCA4 | VHL 207/4885L3MBTL1 4548/4885MAPT 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.